Enzymes Of The Cholinesterase Family

The Fifth International Meeting on Cholinesterases convened in Madras, India, in September of 1994. The long and rich history and culture of India provided an excellent setting for the meeting. More than 120 delegates from Asia, Australia, Europe and North America heard 54 oral presentations and viewed 54 posters on current research on enzymes of the cholinesterase family. The aim of this book is to compile the presentations of the Fifth International Meeting on Cholinesterases into a volume that describes recent investigations on the structure and catalytic function of acetylcholinesterase (AChE), butyrylcholinesterase (BuChE) and related enzymes, as well as studies on the molecular and cellular biology of these enzymes and the genes which encode them. Cholinesterases enjoy a long and storied history in diverse areas. In basic biochemical research, AChE is one of the best studied, though yet enigmatic, of enzymes. The efficient catalytic function of this enzyme presents the biochemist with a fundamental challenge in understanding the relationship between structure and function. AChE and BuChE belong to a family of proteins, the alB hydrolase fold family, whose constituents evolutionarily diverged from a common ancestor. Proteins in this family have a wide range of physiological functions. In commerce, AChE is a prime target for agricultural insect control, and for the development of therapeutic agents for Alzheimer's disease.

Cholinesterase is a family of enzymes that catalyze the hydrolysis of the neurotransmitter acetylcholine into choline and acetic acid, a reaction necessary to allow a cholinergic neuron to return to its resting state after activation. Cholinesterases are the target enzyme of numerous pesticides and chemical warfare agents and have been used for over two decades in the detection of these compounds. In this book, the authors present current research in the production, uses and health effects of cholinesterase. Topics discussed include cholinergic therapy for autistic spectrum disorders; acetylcholinesterase inhibitors in the treatment of Alzheimer's disease; use of fish brain and muscle acetylcholinesterase as a biomarker to monitor water pollution and the evolutionary aspects of molecular forms and biological functions of acetylcholinesterase. (Imprint: Nova)

Basic Neurochemistry: Principles of Molecular, Cellular, and Medical Neurobiology, the outstanding and comprehensive classic text on neurochemistry, is now newly updated and revised in its Eighth Edition. For more than forty years, this text has been the worldwide standard for information on the biochemistry of the nervous system, serving as a resource for postgraduate trainees and teachers in neurology, psychiatry, and basic neuroscience, as well as for medical, graduate, and postgraduate students and instructors in the neurosciences. The text has evolved, as intended, with the science. It is also an excellent source of current information on basic biochemical and cellular processes in brain function and neurological diseases for continuing medical education and qualifying examinations. This text continues to be the standard reference and textbook for exploring the translational nature of neuroscience, bringing basic and clinical neuroscience together in one authoritative volume. Our book title reflects the expanded attention to these links between neurochemistry and neurologic disease. This new edition continues to cover the basics of neurochemistry as in the earlier editions, along with expanded and additional coverage of new research from: Intracellular trafficking; Stem cells, adult neurogenesis, regeneration; Lipid messengers; Expanded coverage of all major neurodegenerative and psychiatric disorders; Neurochemistry of addiction; Neurochemistry of pain; Neurochemistry of hearing and balance; Neurobiology of learning and memory; Sleep; Myelin structure, development, and disease; Autism; and Neuroimmunology. Completely updated text with new authors and material, and many entirely new chapters Over 400 fully revised figures in splendid color 61 chapters covering the range of cellular, molecular and medical neuroscience Translational science boxes emphasizing the connections between basic and clinical neuroscience Companion website at http://elsevierdirect.com/companions/9780123749475

Discovery and Development of Neuroprotective Agents from Natural Products draws together global research on medicinal agents from natural sources as starting points for the design of neuroprotective drugs. From the prediction of promising leads and identification of active agents to the extraction of complex molecules, the book explores a range of important topics to support the development of safer, more economical therapeutics for these increasingly prevalent diseases. Beginning with an overview of current developments in the field, the book goes on to explore the identification, extraction and phytochemistry of such neuroprotective agents as antioxidants, biophenols and naturally occurring anti-inflammatory steroid analogues. Specific natural sources of bioactive agents are reviewed, and the development of these agents into therapeutics for a number of specific neurological disorders, including Alzheimer’s disease, Parkinson’s disease and ischemic brain stroke, are discussed. Combining the expertise of specialists from around the world, this in the Natural Products Drug Discovery series aims to support and encourage researchers in the investigation of natural sources as starting points for the development of standardized, safe and effective neuroprotective drugs. Features chapters written by active researchers and leading global experts deeply engaged in the research field of natural product chemistry for drug discovery Includes comprehensive coverage of cutting-edge research advances in the design of drugs from natural products targeted at different kinds of neurodegenerative diseases Offers a practical review of identification, isolation and extraction techniques to support medicinal chemists in the lab

Marine Ecotoxicology: Current Knowledge and Future Issues is the first unified resource to cover issues related to contamination, responses, and testing techniques of saltwater from a toxicological perspective. With its unprecedented focus on marine environments and logical chapter progression, this book is useful to graduate students, ecotoxicologists, risk assessors, and regulators involved or interested in marine waters. As human interaction with these environments increases, understanding of the pollutants and toxins introduced into the oceans becomes ever more critical, and this book builds a foundation of knowledge to assist scientists in studying, monitoring, and making decisions that affect both marine environments and human health. A team of world renowned experts provide detailed analyses of the most common contaminants in marine environments and explain the design and purpose of toxicity testing methods, while exploring the future of ecotoxicology studies in relation to the world’s oceans. As the threat of increasing pollution in marine environments becomes an ever more tangible reality, Marine Ecotoxicology offers insights and guidance to mitigate that threat. Provides practical tools and methods for assessing and monitoring the accumulation and effects of contaminants in marine environments Unites world renowned experts in marine ecotoxicology to deliver thorough and diverse perspectives Builds the foundation required for risk assessors and regulators to adequately assess and monitor the impact of pollution in marine environments Offers helpful insights and guidance to graduate students, ecotoxicologists, risk assessors, and regulators interested in mitigating threats to marine waters

The VA National Formulary generated controversy, which motivated congressional scrutiny and a directive to the VA to commission this report reviewing the experience with the National Formulary and formulary system. This Institute of Medicine committee was pleased to assist the Congress with this review, in part because the committee saw in the VHA example an opportunity to understand and anticipate problems that all publicly funded programs are likely to encounter in this new age of pharmaceuticals. The Congress asked the committee to review the restrictiveness of the National Formulary, its impact on the costs and quality of care in the VHA, and how it compared to formularies and drug management practices in the private sector and in other public programs, especially Medicaid. Detailed in the pages that follow, the committee's findings and conclusions on these questions are, the committee believes, highly instructive, though not always in the ways that we anticipated.